Treating erectile dysfunction when PDE5 inhibitors fail.
about
Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an updatePharmacogenetics of erectile dysfunction: navigating into uncharted watersAdipose tissue-derived stem cell therapy for erectile dysfunction in rats: a systematic review and meta-analysis.Sexual dysfunction in 2013: Advances in epidemiology, diagnosis and treatmentEndogenous urotensin II selectively modulates erectile function through eNOSThe relaxation effect and mechanism of action of higenamine in the rat corpus cavernosum.Twelve-Month Efficacy and Safety of Low-Intensity Shockwave Therapy for Erectile Dysfunction in Patients Who Do Not Respond to Phosphodiesterase Type 5 Inhibitors.Effect of sildenafil on erectile dysfunction and improvement in the quality of sexual life in China: a multi-center study.Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction.Recruiting endogenous stem cells: a novel therapeutic approach for erectile dysfunctionReview article: addressing the sexual health of patients with COPD: the needs of the patient and implications for health care professionals.Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction.The use of phosphodiesterase 5 inhibitors with concomitant medications.Hydrogen sulfide and erectile function: a novel therapeutic target.Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction.An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.Daily dosing of PDE5 inhibitors: where does it fit in?Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction.PDE5 inhibitors: considerations for preference and long-term adherence.Stem-cell therapy for erectile dysfunction.Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study.Pomegranate juice causes a partial improvement through lowering oxidative stress for erectile dysfunction in streptozotocin-diabetic rat.Avanafil - a further step to tailoring patient needs and expectations.VEGF genetic polymorphisms affect the responsiveness to sildenafil in clinical and postoperative erectile dysfunction.Effects of chronic treatment with the eNOS stimulator Impaza on penis length and sexual behaviors in rats with a high baseline of sexual activity.Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor.Delivery of intracavernosal therapies using needle-free injection devices.Lesion Pattern in Patients With Erectile Dysfunction of Suspected Arterial Origin: An Angiographic Study.[Avanafil for the treatment of erectile dysfunction in practice. Non-interventional study AVANTI].Transdermal water-in-oil nanocarriers of nitric oxide for triggering penile erection.
P2860
Q26775925-0B175FB3-B704-43CE-9D2E-24CF1C21096FQ28249515-7A65ED62-B0CC-442F-8641-61DDCB38B9D2Q30234763-E3D6B535-244C-4806-A151-DBE96A445102Q30398989-702E93A1-5F81-4FE1-A29D-435109EAD138Q34154714-85886D56-F831-4050-8FC8-AEE0B1F2C351Q34220107-0D037631-D94D-4D33-918D-167D550D2711Q34677900-B277ADE4-22A7-4696-877D-261628A7E0A5Q36046815-48BA466E-9520-4133-80AF-6A35DE9F52AEQ36056990-786A7C07-C717-466E-A9DA-76ABF6E6E831Q36530167-1F32103F-6DE4-438D-8BEA-F0253D1A6EA2Q36875644-6A9877F6-B106-4AFE-B0C2-81A6D3CC1B01Q37165058-EEE6CF94-30C3-4014-9017-3AFF77765E9EQ37321940-1DA87B78-5C4F-45C3-B904-91D64CEFB946Q37862060-0DAC3533-F66D-463E-AE52-45B9DD4648A8Q37905563-B04538E4-DFBC-4E75-82B2-F3379EE1777AQ38107001-333FCE9A-65C0-4605-8240-62E583365529Q38115198-96901CA2-F72C-458C-8EBD-EEE401E1442CQ38118626-56DD3191-B3FC-47E7-9BB0-5157F77D1915Q38122721-755D918B-326B-4C67-B669-E7C0104EEF57Q38148781-AB92CCDB-1A52-4888-96CF-99181A99DF93Q38550859-F189B2AB-3AB4-4356-9C43-EA20E91FD2F0Q38825714-F3C0ADAC-2C21-44FD-B073-6BE2FB381F3CQ38846047-927DCA90-DA1B-4D84-978B-94545F27640CQ44256449-4B4EC6B7-9FF5-4C23-8071-A77D4303C260Q46207607-A197C052-9A60-48D8-9B04-6F8D0F1F0902Q47812722-A00D51F2-5758-4495-A1B4-CFA613E1B7CAQ47876507-92A68386-39FD-46AC-B0FB-7552BFED66E0Q48578839-CBE505AD-2221-422A-8D95-7B882AFA0436Q52837854-F90C46D9-04E7-449B-B932-3239D3F3866FQ55081600-371AE979-60A8-4132-8C12-A3BF340FB529
P2860
Treating erectile dysfunction when PDE5 inhibitors fail.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Treating erectile dysfunction when PDE5 inhibitors fail.
@ast
Treating erectile dysfunction when PDE5 inhibitors fail.
@en
type
label
Treating erectile dysfunction when PDE5 inhibitors fail.
@ast
Treating erectile dysfunction when PDE5 inhibitors fail.
@en
prefLabel
Treating erectile dysfunction when PDE5 inhibitors fail.
@ast
Treating erectile dysfunction when PDE5 inhibitors fail.
@en
P2093
P2860
P356
P1433
P1476
Treating erectile dysfunction when PDE5 inhibitors fail.
@en
P2093
Chelsea N McMahon
Christopher J Smith
Ridwan Shabsigh
P2860
P304
P356
10.1136/BMJ.332.7541.589
P407
P577
2006-03-01T00:00:00Z